Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype.

The Journal of experimental medicine - 1 Apr 2024

Sharma Naveen, Fan Xiaozhou, Atolagbe Oluwatomisin T, Ge Zhongqi, Dao Kelly N, Sharma Padmanee, Allison James P

Abstract excerpt

We have previously demonstrated synergy between ICOS costimulation (IVAX; ICOSL-transduced B16-F10 cellular vaccine) and CTLA-4 blockade in antitumor therapy. In this study, we employed CyTOF and single-cell RNA sequencing and observed significant remodeling of the lymphoid and myeloid compartments in combination therapy. Compared with anti-CTLA-4 monotherapy, the combination therapy enriched Th1 CD4 T cells,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD8-Positive T-Lymphocytes
Share to CTLA-4 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inducible T-Cell Co-Stimulator Protein

Share to Neoplasms

Share to Phenotype

Share to Tumor-Associated Macrophages

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 38517331
DOI: 10.1084/jem.20231263
PMCID: PMC10959121

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype.PMID 38517331Read ↗

Therapeutic Blockade of Type 2 Cytokines and PD1 Unleashes Anti-Tumor Immunity Through Coordinated Reprogramming of Innate and Adaptive Immune SurveillanceSemantic proximity Read ↗

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cellsSemantic proximity Read ↗

Breaking the immunosuppressive barrier: an armored CAR-M biotechnology with the original M1 phenotype dominance rescues antitumor immunity.Semantic proximity Read ↗

Engineered GM-CSF polarizes protumorigenic tumor-associated macrophages to an antitumorigenic phenotype and potently synergizes with IL-12 immunotherapy.Semantic proximity Read ↗

Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and MetastasisSemantic proximity Read ↗

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.Semantic proximity Read ↗

ImmTACs overcome cytotoxic T cell suppressionSemantic proximity Read ↗

HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants.Semantic proximity Read ↗

An immune-stimulating antibody conjugate spatiotemporally targeting CD47 and TLR9 elicits macrophage-dependent tumor clearance and durable anti-cancer adaptive immunitySemantic proximity Read ↗

Caerin 1.1/1.9-mediated antitumor immunity depends on IFNAR-Stat1 signalling of tumour infiltrating macrophage by autocrine of IFNα and is enhanced by CD47 blockadeSemantic proximity Read ↗

In Situ Synthesis of an Immune-Checkpoint Blocker from Engineered Bacteria Elicits a Potent Antitumor ResponseSemantic proximity Read ↗

Enhancing CAR T cell persistence through ICOS and 4-1BB costimulationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.